Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:CGEMOTCMKTS:IPHYFNASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$2.07+8.4%$1.43$1.11▼$5.00$550.91M1.771.53 million shs5.90 million shsCGEMCullinan Therapeutics$8.96+2.4%$7.88$6.85▼$24.76$528.77M-0.07574,084 shs338,659 shsIPHYFInnate Pharma$1.45$1.66$1.45▼$1.76$121.55M0.551,445 shsN/ARGNXREGENXBIO$10.13-2.1%$7.97$5.04▼$15.36$508.12M1.11903,394 shs1.01 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+9.77%+24.03%+41.48%+4.37%-54.42%CGEMCullinan Therapeutics+1.04%+12.04%-0.46%+7.63%-62.77%IPHYFInnate Pharma0.00%0.00%0.00%-50.00%-34.09%RGNXREGENXBIO+19.24%+6.59%-0.48%+74.83%-27.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics2.728 of 5 stars3.51.00.00.03.43.30.6CGEMCullinan Therapeutics2.3767 of 5 stars3.52.00.00.02.81.70.6IPHYFInnate Pharma0.1635 of 5 stars0.01.00.00.01.81.70.0RGNXREGENXBIO4.2205 of 5 stars3.41.00.04.63.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32350.24% UpsideCGEMCullinan Therapeutics 3.00Buy$32.00257.14% UpsideIPHYFInnate Pharma 0.00N/AN/AN/ARGNXREGENXBIO 2.83Moderate Buy$31.63212.19% UpsideCurrent Analyst Ratings BreakdownLatest IPHYF, CGEM, AUTL, and RGNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/16/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/21/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $6.003/20/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/18/2025RGNXREGENXBIOLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.003/17/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.003/14/2025RGNXREGENXBIOMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.003/14/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M61.14N/AN/A$0.64 per share3.23CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.61 per shareN/AIPHYFInnate Pharma$66.71M1.82N/AN/A$0.70 per share2.07RGNXREGENXBIO$156.72M3.24N/AN/A$7.09 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%8/14/2025 (Estimated)CGEMCullinan Therapeutics-$153.16M-$2.91N/AN/AN/AN/A-26.54%-25.32%8/14/2025 (Estimated)IPHYFInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/ARGNXREGENXBIO-$263.49M-$3.11N/AN/AN/A-283.19%-70.65%-41.68%8/7/2025 (Estimated)Latest IPHYF, CGEM, AUTL, and RGNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69CGEMCullinan TherapeuticsN/A24.4624.46IPHYFInnate PharmaN/AN/AN/ARGNXREGENXBION/A3.053.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CGEMCullinan Therapeutics86.31%IPHYFInnate PharmaN/ARGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CGEMCullinan Therapeutics7.16%IPHYFInnate Pharma31.89%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableCGEMCullinan Therapeutics3059.02 million54.69 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableRGNXREGENXBIO37050.16 million43.04 millionOptionableIPHYF, CGEM, AUTL, and RGNX HeadlinesRecent News About These CompaniesREGENXBIO (NASDAQ:RGNX) Shares Up 13.5% - Still a Buy?June 3 at 1:54 PM | marketbeat.comShort Interest in REGENXBIO Inc. (NASDAQ:RGNX) Expands By 21.9%June 3 at 10:07 AM | marketbeat.comBank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)June 3 at 3:18 AM | marketbeat.comREGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202June 2 at 7:05 AM | prnewswire.comTwo Sigma Advisers LP Acquires 112,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 1 at 3:59 AM | marketbeat.comTwo Sigma Investments LP Acquires 263,495 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 1 at 3:58 AM | marketbeat.comFY2026 EPS Estimates for REGENXBIO Increased by AnalystMay 31 at 6:44 AM | marketbeat.comMillennium Management LLC Buys 1,061,187 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 26, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires 75,652 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 25, 2025 | marketbeat.comQ2 Earnings Forecast for REGENXBIO Issued By Leerink PartnrsMay 24, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Jane Street Group LLCMay 23, 2025 | marketbeat.comRegenxbio at RBC Conference: Strategic Moves and Clinical ProgressMay 22, 2025 | investing.comREGENXBIO FY2025 EPS Forecast Reduced by Chardan CapitalMay 21, 2025 | marketbeat.comREGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 20, 2025 | finanznachrichten.deREGENXBIO announces royalty monetization agreement for up to $250MMay 20, 2025 | msn.comREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 19, 2025 | prnewswire.comPoint72 Asia Singapore Pte. Ltd. Makes New $447,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)May 18, 2025 | marketbeat.comHudson Bay Capital Management LP Has $2.38 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)May 16, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in StockMay 15, 2025 | insidertrades.comUS FDA accepts and grants priority review status to Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis IIMay 15, 2025 | pharmabiz.comEarnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their ForecastsMay 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHYF, CGEM, AUTL, and RGNX Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$2.07 +0.16 (+8.38%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.03 (+1.21%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Cullinan Therapeutics NASDAQ:CGEM$8.96 +0.21 (+2.40%) Closing price 04:00 PM EasternExtended Trading$8.96 +0.00 (+0.06%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Innate Pharma OTCMKTS:IPHYF$1.45 0.00 (0.00%) As of 06/2/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.REGENXBIO NASDAQ:RGNX$10.13 -0.22 (-2.13%) Closing price 04:00 PM EasternExtended Trading$10.35 +0.22 (+2.17%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
